特宝生物(688278) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥968.93 million, an increase of 26.68% compared to the same period last year[2] - The total profit for the quarter was ¥254.73 million, reflecting a decrease of 9.08% year-over-year[2] - Net profit attributable to shareholders was ¥238.23 million, down 4.63% from the previous year[2] - The basic earnings per share for the quarter was ¥0.59, a decrease of 3.28% compared to the same period last year[2] - Total revenue for the first three quarters of 2025 reached CNY 2,479,547,947.46, a 26.7% increase from CNY 1,954,701,664.76 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 666,123,781.87, representing a 20.2% increase compared to CNY 554,149,217.81 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 1.64, up from CNY 1.36 in the same period of 2024[21] Research and Development - Research and development expenses totaled ¥109.54 million, an increase of 22.90% year-over-year, representing 11.31% of operating revenue[3] - Research and development expenses for the first three quarters of 2025 totaled CNY 279,335,347.75, an increase of 44.5% from CNY 193,341,950.18 in 2024[20] Assets and Liabilities - Total assets at the end of the quarter were ¥3.79 billion, a 24.12% increase from the end of the previous year[3] - Total assets as of the reporting date were CNY 3,786,248,215.19, compared to CNY 3,050,414,835.58 in the previous year[18] - Total liabilities increased to CNY 776,988,289.04 from CNY 497,098,543.83 year-over-year[18] - Non-current assets totaled CNY 1,551,638,564.12, up from CNY 1,223,324,670.50 in the previous year[18] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥471.12 million, an increase of 61.33%[3] - Cash flow from operating activities for the first three quarters of 2025 was CNY 2,454,222,650.87, compared to CNY 1,895,427,035.95 in 2024[23] - Net cash flow from operating activities amounted to ¥471,118,206.70, an increase from ¥292,015,044.33 year-over-year[24] - Cash inflow from investment activities totaled ¥1,047,660,067.17, compared to ¥548,482,799.76 in the previous period[24] - Net cash flow from financing activities was -¥83,917,940.47, a decrease from -¥171,371,528.22 year-over-year[25] Shareholder Information - The company reported a total of 8,608 common shareholders at the end of the reporting period[8] - Major shareholder Yang Ying holds 33.94% of the shares, with a total of 138,077,266 shares[8] Current Assets - As of September 30, 2025, the company's total current assets amounted to RMB 2,234,609,651.07, an increase from RMB 1,827,090,165.08 as of December 31, 2024, reflecting a growth of approximately 22.3%[16] - The company's cash and cash equivalents increased to RMB 449,450,206.30 from RMB 371,821,698.43, representing a growth of about 20.9%[16] - Accounts receivable rose to RMB 788,908,929.03 from RMB 771,496,539.39, indicating a slight increase of approximately 2.3%[16] - Inventory levels increased to RMB 374,644,060.24 from RMB 263,546,426.51, marking a significant rise of around 42.2%[16] Donations and Community Projects - The company has committed to additional donations totaling RMB 8 million for various hepatitis-related projects, with RMB 600,000 already donated during the reporting period[11] - The company has donated RMB 540,000 to the "Oasis Project" aimed at reducing liver cancer incidence among hepatitis patients, with total donations reaching RMB 3,370,000 to date[12] - The company has pledged RMB 900,000 for HBV-related liver cancer prevention projects, with RMB 200,000 donated so far[13] - The company has also committed RMB 1 million to the "Little Bamboo Shoot" children's health project, with RMB 250,000 already contributed[13] Fixed Assets - The company’s fixed assets increased to RMB 608,598,977.21 from RMB 496,526,291.01, reflecting a growth of approximately 22.5%[16] - The company’s construction in progress rose to RMB 267,704,214.37 from RMB 181,556,607.69, indicating an increase of about 47.5%[16]